TABLE 1.
Baseline demographics of survey respondents
| Number of responses (% of cohort) | Dermatologists | Other cancer specialists (OCS) | |
|---|---|---|---|
| Total respondents | 156 | 89 (57.05%) | 67 (42.95%) |
| Specialty | |||
| Med Dermatology/Dermatology Oncology | 14 (8.97%) | ||
| Mohs | 75 (48.08%) | ||
| Medical Oncology | 15 (9.62%) | ||
| Surgical Oncology | 1 (0.64%) | ||
| ENT/Head and Neck Surgery | 27 (17.31%) | ||
| Plastic Surgery | 3 (1.92%) | ||
| Radiation Oncology | 21 (13.46%) | ||
| Region | |||
| USA | 148 (94.87%) | 83 (93.26%) | 65 (97.01%) |
| UK | 5 (3.21%) | 5 (5.62%) | 0 |
| Canada | 2 (1.28%) | 1 (1.12%) | 1 (1.49%) |
| Australia/New Zealand | 1 (0.64%) | 0 | 1 (1.49%) |
| Europe | 0 | 0 | 0 |
| Number of HRCSCC treated in the past 12 months | |||
| 0 | 0 | 0 | 0 |
| 1–10 | 25 (16.03%) | 12 (13.48%) | 13 (19.40%) |
| 11–25 | 75 (48.08%) | 45 (50.56%) | 30 (44.78%) |
| 26–50 | 32 (20.51%) | 14 (15.73%) | 18 (26.87%) |
| >50 | 24 (15.38%) | 18 (20.22%) | 6 (9.95%) |
| Number of years in practice (post‐residency) | |||
| 0–5 | 46 (29.49%) | 27 (30.34%) | 19 (28.36%) |
| 6–10 | 45 (28.85%) | 27 (30.34% | 18 (26.87%) |
| 11–20 | 36 (23.08%) | 19 (21.37%) | 17 (25.37%) |
| >20 | 29 (18.59%) | 16 (17.98%) | 13 (19.40%) |
| Practice environment | |||
| Academics | 136 (87.18%) | 72 (80.90%) | 64 (95.52%) |
| Private practice/closed multi‐specialty | 31 (19.87%) | 22 (24.72%) | 5 (7.46%) |
| VA | 7 (4.49%) | 6 (6.74%) | 1 (1.49%) |
| Open multi‐specialty group | 1 (0.64%) | 1 (1.12%) | 0 |
Abbreviation: HRSCC, high‐risk squamous cell carcinoma.